Skip to content

Cognitive impairments from developmental exposure to serotonergic drugs: citalopram and MDMA

Tori L. Schaefer, Curtis E. Grace, A Braun, Robyn M. Amos‐kroohs, Devon L. Graham, Matthew R. Skelton, Michael T. Williams, Charles V. Vorhees

The International Journal of Neuropsychopharmacology January 11, 2013 DOI: 10.1017/s1461145712001447 via OpenAlex

Summary

AI-generated from the abstract

In rats, treatment with the recreational drug MDMA during a developmental period equivalent to the human third trimester causes long-term spatial and egocentric learning and memory deficits, along with serotonin reductions. Pretreatment with the antidepressant citalopram, a selective serotonin reuptake inhibitor, did not prevent these cognitive deficits. Unexpectedly, citalopram alone produced learning deficits as severe as those caused by MDMA. These are the first findings showing cognitive impairments from developmental exposure to a selective serotonin reuptake inhibitor, suggesting the need for further research on the long-term safety of antidepressants during pregnancy.

Study at a glance

Characteristics Controlled experiment Peer reviewed
Population Rat pups treated on postnatal days 11-20
Interventions MDMA Citalopram
Dose 10 mg/kg × 4/d at 2 h intervals for MDMA; 5 or 7.5 mg/kg × 2/d for citalopram
Topics MDMA Serotonin
Keywords Citalopram Psychology Serotonin reuptake inhibitor
Citations 24
Key finding Citalopram pretreatment did not attenuate MDMA-induced cognitive deficits, and citalopram alone caused learning deficits as severe as MDMA.

Abstract

Abstract We previously showed that developmental 3,4-methylenedioxymethamphetamine (MDMA) treatment induces long-term spatial and egocentric learning and memory deficits and serotonin (5-HT) reductions. During brain development, 5-HT is a neurotrophic factor influencing neurogenesis, synaptogenesis, migration, and target field organization. MDMA (10 mg/kg × 4/d at 2 h intervals) given on post-natal day (PD) 11–20 in rats (a period of limbic system development that approximates human third trimester brain development) induces 50% reductions in 5-HT during treatment and 20% reductions when assessed as adults. To determine whether the 5-HT reduction is responsible for the cognitive deficits, we used citalopram (Cit) pretreatment to inhibit the effects of MDMA on 5-HT reuptake in a companion study. Cit attenuated MDMA-induced 5-HT reductions by 50% (Schaefer et al., 2012). Here we tested whether Cit (5 or 7.5 mg/kg × 2/d) pretreatment attenuates the cognitive effects of MDMA. Within each litter, different offspring were treated on PD11–20 with saline (Sal) + MDMA, Cit + MDMA, Cit + Sal or Sal + Sal. Neither spatial nor egocentric learning/memory was improved by Cit pretreatment. Unexpectedly, Cit + Sal (at both doses) produced spatial and egocentric learning deficits as severe as those caused by Sal + MDMA. These are the first data showing cognitive deficits resulting from developmental exposure to a selective serotonin reuptake inhibitor. These data indicate the need for further research on the long-term safety of antidepressants during pregnancy.

Explore topics

Comments

No comments yet.

Log in to comment